November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 14th, 2026The OncFive: Top Oncology Articles for the Week of 11/8The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.Read more
November 13th, 2026CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 InhibitionA European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.Read more
November 11th, 2026LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCCThomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.Read more
November 9th, 2026Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple MyelomaThe decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.Read more
November 9th, 2026FDA Flashback: Hematologic Cancer Decisions and News From October 2026Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.Read more
November 9th, 2026BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaDuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.Read more
November 8th, 2026Five Under 5: Top Oncology Videos for the Week of 11/1The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.Read more